Mylan wins generic Prilosec suit

PITTSBURGH The U.S. Court of Appeals for the Federal Circuit ruled that Mylan’s generic version of AstraZeneca’s Prilosec does not infringe on AstraZeneca’s patents, Mylan announced Tuesday.

Prilosec (omeprazole) is designed to treat frequent heartburn. Mylan began selling generic omeprazole on Aug. 4, 2003, despite the litigation by AstraZeneca.

Prilosec had sales of $1.14 billion in 2007, according to AstraZeneca financial data.